A pharmacist-led service significantly improved SGLT2 inhibitor use among primary care patients with chronic kidney disease and heart failure.
Does a pharmacist-led service improve SGLT2 inhibitor use in patients with CKD and HF in the primary care setting?
Patients with chronic kidney disease (CKD) and heart failure (HF) in the primary care setting
Pharmacist-led service (DCES-credentialed pharmacists in an interprofessional care team) to initiate SGLT2 inhibitor therapy
SGLT2 inhibitor use
A pharmacist-led service is feasible and significantly improves the initiation of SGLT2 inhibitors for patients with CKD and HF in primary care.
This initiative resulted in a significant improvement in SGLT2 inhibitor use for patients with CKD and HF. The findings highlight the feasibility of using DCES-credentialed pharmacists in an interprofessional care team to initiate SGLT2 inhibitor therapy for patients with these conditions in the primary care setting.
Building similarity graph...
Analyzing shared references across papers
Loading...
Stacey Cutrell
Kiara Patino
R. Oluwafunmito Babalola
The Science of Diabetes Self-Management and Care
Virginia Commonwealth University
University of North Texas
University of North Texas Health Science Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Cutrell et al. (Wed,) reported a other. A pharmacist-led service significantly improved SGLT2 inhibitor use among primary care patients with chronic kidney disease and heart failure.
www.synapsesocial.com/papers/69d896676c1944d70ce07c32 — DOI: https://doi.org/10.1177/26350106261431283